NorthWest Biotherapeutics Inc (NWBO)

[antihama]

And if it turns out that the company has been allowed to adjudicate their endpoints to better determine if early PFS events really weren't early PFS events in the treatment patients, then PFS may indeed still be in play

Senti, I am having trouble seeing that a revised decision on whether a pt had a PFS event will help the trial that much since I see that determination happening after the fact. For instance, the trial is ongoing and a patient has a PFS event and crosses over. Later on, they review the MRI and determine that that pt had a psPD event and shouldn’t have crossed over. They can’t un-crossover that pt so what do they do? Eliminate that pt from the calculations? I’m just not seeing it. However, I don’t have these type concerns to begin with since multiple scans are used before a pt is determined to have progression.